7.72
Schlusskurs vom Vortag:
$7.96
Offen:
$7.93
24-Stunden-Volumen:
18,844
Relative Volume:
0.33
Marktkapitalisierung:
$54.37M
Einnahmen:
$100.44M
Nettoeinkommen (Verlust:
$-133.16M
KGV:
-0.2997
EPS:
-25.76
Netto-Cashflow:
$-94.85M
1W Leistung:
-2.03%
1M Leistung:
-1.03%
6M Leistung:
-41.87%
1J Leistung:
-9.18%
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Firmenname
Atara Biotherapeutics Inc
Sektor
Branche
Telefon
805-623-4211
Adresse
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Vergleichen Sie ATRA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ATRA
Atara Biotherapeutics Inc
|
7.72 | 54.37M | 100.44M | -133.16M | -94.85M | -25.76 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-11-09 | Herabstufung | Evercore ISI | Outperform → In-line |
2023-11-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2023-11-09 | Herabstufung | Mizuho | Buy → Neutral |
2022-07-20 | Herabstufung | Citigroup | Neutral → Sell |
2022-07-13 | Herabstufung | JP Morgan | Overweight → Neutral |
2022-07-13 | Herabstufung | Stifel | Buy → Hold |
2022-05-10 | Herabstufung | Citigroup | Buy → Neutral |
2021-05-13 | Hochstufung | JP Morgan | Neutral → Overweight |
2020-12-09 | Herabstufung | Citigroup | Buy → Neutral |
2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
2020-11-10 | Bestätigt | H.C. Wainwright | Buy |
2020-06-30 | Eingeleitet | Evercore ISI | Outperform |
2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
2020-04-23 | Hochstufung | Citigroup | Neutral → Buy |
2019-11-08 | Herabstufung | JP Morgan | Overweight → Neutral |
2019-09-27 | Herabstufung | Goldman | Neutral → Sell |
2019-09-16 | Herabstufung | Jefferies | Buy → Hold |
2019-06-04 | Hochstufung | Citigroup | Sell → Neutral |
2019-05-30 | Eingeleitet | ROTH Capital | Buy |
2019-05-23 | Eingeleitet | Stifel | Buy |
2019-01-23 | Eingeleitet | Mizuho | Buy |
2018-04-10 | Eingeleitet | JP Morgan | Overweight |
2018-03-16 | Eingeleitet | Guggenheim | Neutral |
2018-03-05 | Bestätigt | Jefferies | Buy |
2018-02-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
2018-02-15 | Herabstufung | Citigroup | Neutral → Sell |
2018-01-03 | Hochstufung | Citigroup | Sell → Neutral |
2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Atara Biotherapeutics Holds Annual Stockholders Meeting - TipRanks
Long Term Trading Analysis for (ATRA) - news.stocktradersdaily.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Northern Trust Corp Purchases New Position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Defense World
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Short Interest Update - Defense World
Bank of America Corp DE Acquires 1,543 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Defense World
Redmile Group, LLC's Strategic Acquisition in Atara Biotherapeutics Inc - GuruFocus
Here's Why You Should Consider Buying Atara Biotherapeutics Stock - Barchart.com
Biotech Pioneer Pascal Touchon Joins CDR-Life Board: Former Atara CEO to Drive T Cell Platform Innovation - Stock Titan
(ATRA) Trading Advice - news.stocktradersdaily.com
Atara Biotherapeutics (NASDAQ:ATRA) & Turnstone Biologics (NASDAQ:TSBX) Financial Analysis - Defense World
Top Executives at Atara Biotherapeutics Make Significant Stock Sales! - TipRanks
Atara Biotherapeutics Executives Sell Shares for Tax Obligations - TradingView
Citadel Advisors LLC Has $3.56 Million Position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Defense World
FDA Delivers Blow to ImmunityBio - Los Angeles Business Journal
Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors - BioSpace
Atara Biotherapeutics (ATRA) Expands Board Following $16 Million Offering | ATRA Stock News - GuruFocus
Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors | ATRA Stock News - GuruFocus
Atara Biotherapeutics Reports Strong Q1 2025 Results - TipRanks
(ATRA) Investment Analysis and Advice - news.stocktradersdaily.com
Atara Biotherapeutics Announces $16M Stock Offering - TipRanks
Atara Biotherapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Atara Biotherapeutics: Q1 Earnings Snapshot - CT Insider
Atara Biotherapeutics sets stock and warrant offering prices By Investing.com - Investing.com India
Atara Biotherapeutics prices $16M public offering - MSN
Atara Biotherapeutics (ATRA) Announces $16M Share Offering - GuruFocus
Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress | ATRA Stock News - GuruFocus
Atara Biotherapeutics sets stock and warrant offering prices - Investing.com
Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress - BioSpace
Atara Biotherapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Atara Biotherapeutics Announces Pricing of $16 Million Offering - GuruFocus
Atara Biotherapeutics, Inc. SEC 10-Q Report - TradingView
Atara Biotherapeutics Announces Pricing of $16 Million Offering | ATRA Stock News - GuruFocus
Atara Biotherapeutics Announces Major Workforce Reduction - TipRanks
Atara Biotherapeutics To Reduce Workforce By 30% - marketscreener.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Finanzdaten der Atara Biotherapeutics Inc-Aktie (ATRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Atara Biotherapeutics Inc-Aktie (ATRA) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Nguyen AnhCo | President and CEO |
May 16 '25 |
Sale |
6.76 |
3,276 |
22,156 |
70,847 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):